Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8444260 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
The incidence of cardiotoxicity associated with raltitrexed in patients with advanced CRC treated is favourable in a highly skewed, at-risk patient population, all of whom had documented cardiotoxicity with other fluoropyrimidines or were unable to tolerate capecitabine due to cardiac history. Raltitrexed is therefore a suitable option for patients with fluoropyrimidine-induced cardiotoxicity or significant cardiovascular risk factors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Claire Kelly, Neel Bhuva, Mark Harrison, Andrew Buckley, Mark Saunders,